Almost A Quarter Of Bristol-Myers Squibb's Valuation Is Dependent On Yervoy's & Nivolumab's Growth

Well, here is a fun fact for you. Around 20-25% of Bristol-Myers Squibb?s valuation is based on the expected growth of its cancer drugs, primarily Yervoy and Nivolumab. In other words, if the growth in these drugs was to flatten out, BMY would be a $50 stock according to our estimate. Our current price estimate for Bristol-Myers Squibb stands at $66, implying a premium of around 5% to the market. Oncology drugs constitute the most valuable division for the company, accounting for about 40% of it...